Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Apr. 15, 2025 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | Interpace Biosciences, Inc. (“Interpace,” the “Company,” “we”, “us” or “our”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025 (the “Original Filing”).We are filing this Amendment solely for the purpose of including in Part III the information that was to be incorporated by reference from the Company’s definitive proxy statement for its 2025 Annual Meeting of Stockholders because the Company’s definitive proxy statement will not be filed with the SEC within 120 days after the end of the Company’s fiscal year ended December 31, 2024. This Amendment amends and restates in its entirety Items 10, 11, 12, 13 and 14 of Part III and amends and restates in its entirety Part IV of the Original Filing to include the prior exhibits and additional certifications required of the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, we are not including new certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as described above, no other changes have been made to the Original Filing and the Original Filing continues to speak as of the date of the Original Filing. Except as expressly set forth herein, this Amendment does not reflect events occurring after the date of the Original Filing or modify or update any of the other disclosures contained therein in any way other than as required to reflect the amendments discussed above. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings with the SEC. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2024 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 000-24249 | ||
| Entity Registrant Name | Interpace Biosciences, Inc. | ||
| Entity Central Index Key | 0001054102 | ||
| Entity Tax Identification Number | 22-2919486 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | Waterview Plaza | ||
| Entity Address, Address Line Two | Suite 310 | ||
| Entity Address, Address Line Three | 2001 Route 46 | ||
| Entity Address, City or Town | Parsippany | ||
| Entity Address, State or Province | NJ | ||
| Entity Address, Postal Zip Code | 07054 | ||
| City Area Code | (855) | ||
| Local Phone Number | 776-6419 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 3,999,609 | ||
| Entity Common Stock, Shares Outstanding | 4,414,904 | ||
| Documents Incorporated by Reference [Text Block] | None | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Listing, Par Value Per Share | $ 0.01 | ||
| Auditor Firm ID | 274 | ||
| Auditor Name | EisnerAmper, LLP | ||
| Auditor Location | Philadelphia, Pennsylvania |